Can pressurized oxygen boost stem cell transplants for myeloma?

NCT ID NCT04862676

Completed Disease control Sponsor: University of Rochester Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This early-phase study tested whether repeated hyperbaric oxygen therapy is safe for multiple myeloma patients who are about to receive high-dose chemotherapy and a stem cell transplant. Twenty-nine participants were exposed to 100% oxygen at 2.5 times normal atmospheric pressure for 90-minute sessions. The main goal was to check for serious side effects within 24 hours and longer-term effects up to 100 days after transplant.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: hyperbaric oxygen
What this could lead to: If it works, this could point toward a way to make stem cell transplants safer and more effective for multiple myeloma patients.
What could go wrong: This is a very early, small pilot study with only 29 participants. It only looked at safety, not whether hyperbaric oxygen actually helps treat the cancer. There are also risks like seizures or lung injury from the high-pressure oxygen.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma plasma cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYELOMA

Contacts and locations

Locations

James P. Wilmot Cancer Center at University of Rochester Medical Center

Rochester, New York, 14642-0001, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.